SDGR250117C22500
- 0.01
- 0.000.00%
Schrodinger Newsroom
Stargate Project's Healthcare Winners: AI-led Biotechs and Metagenomi
Schrodinger Is Maintained at Overweight by Keybanc
Schrodinger Analyst Ratings
Schrödinger, Inc. (SDGR): Quantum Mechanics Meets AI in Biopharma, Backed by Hunterbrook's 'Key AI Winner' Endorsement
KeyBanc Maintains Schrodinger(SDGR.US) With Buy Rating, Raises Target Price to $27
Why Schrödinger, Inc. (SDGR) Is Skyrocketing Now
Morgan Stanley Maintains Schrodinger(SDGR.US) With Hold Rating, Raises Target Price to $31
Morgan Stanley Reaffirms Their Hold Rating on Schrodinger (SDGR)
Schrodinger (SDGR) Moves 14.1% Higher: Will This Strength Last?
The chairman of Oracle promotes AI-driven mRNA vaccines, and AI drug developers respond with a surge, with Moderna rising over 7%.
Larry Ellison stated that AI can be used to develop personalized cancer vaccines based on mRNA and for early tumor detection.
Schrodinger Shares Are Trading Higher Following Mention in a Report From Hunterbrook Capital.
Schrodinger Up Nearly 16%, On Track for Largest Percent Increase Since May 2023 -- Data Talk
Moderna Spikes as Oracle's Larry Ellison Touts AI-driven MRNA Vaccines
Watching Schrodinger; Hunterbrook Issues Report On Co Titled "Schrödinger: The Nvidia Biotech Partner Jensen Huang Told To 'Think Bigger'"
Seagate Posts Upbeat Earnings, Joins Netflix, Travelers, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesday
Schrodinger's Growth Potential Bolstered by Strategic Collaborations and Regulatory Milestones
Goldman Sachs Maintains Schrodinger(SDGR.US) With Hold Rating, Maintains Target Price $28
Craig-Hallum Maintains Schrodinger(SDGR.US) With Buy Rating
Craig-Hallum Reaffirms Their Buy Rating on Schrodinger (SDGR)
Schrödinger Unveils Its Strategic Priorities For 2025; Expands Research Collaboration With Otsuka; Expects To Receive Upfront Payment Of $150M From Novartis In Q1 Of 2025